Magnetically active Fe3O4 nanorods loaded with tissue plasminogen activator for enhanced thrombolysis

被引:49
作者
Hu, Jiangnan [1 ,2 ]
Huang, Weijie [3 ]
Huang, Shengwei [1 ,2 ]
ZhuGe, Qichuan [1 ]
Jin, Kunlin [1 ,2 ]
Zhao, Yiping [3 ]
机构
[1] Wenzhou Med Univ, Affiliated Hosp 1, Zhejiang Prov Key Lab Aging & Neurol Disorder Res, Wenzhou 325000, Peoples R China
[2] Univ North Texas, Hlth Sci Ctr, Dept Pharmacol & Neurosci, Ft Worth, TX 76107 USA
[3] Univ Georgia, Dept Phys & Astron, Nanoscale Sci & Engn Ctr, Athens, GA 30602 USA
基金
美国国家科学基金会; 中国国家自然科学基金; 美国国家卫生研究院;
关键词
magnetic nanorods; drug delivery; enhanced thrombolysis; tissue plasminogen activator; iron oxide; ACUTE ISCHEMIC-STROKE; MEDIATED THROMBOLYSIS; NANOPARTICLES; THERAPY; MICROBUBBLES; FIBRINOLYSIS; ALTEPLASE; DISEASE; MODEL; TRIAL;
D O I
10.1007/s12274-016-1152-4
中图分类号
O64 [物理化学(理论化学)、化学物理学];
学科分类号
070304 ; 081704 ;
摘要
Systemic thrombolysis with intravenous tissue plasminogen activator (tPA) remains the only proven treatment that is effective in improving the clinical outcome of patients with acute ischemic stroke. However, thrombolytic therapy has some major limitations such as hemorrhage, neurotoxicity, and the short time window for the treatment. In this study, we designed iron oxide (Fe3O4) nanorods loaded with 6% tPA, which could be released within similar to 30 min. The Fe3O4 nanorods could be targeted to blood clots under magnetic guidance. In addition, the release of tPA could be significantly increased using an external rotating magnetic field, which subsequently resulted in a great improvement in the thrombolytic efficiency. Systematic and quantitative studies revealed the fundamental physical processes involved in the enhanced thrombolysis, while the in vitro thrombolysis assay showed that the proposed strategy could improve thrombolysis and recanalization rates and reduce the risk of tPA-mediated hemorrhage in vivo. Such a strategy will be very useful for the treatment of ischemic stroke and other deadly thrombotic diseases such as myocardial infarction and pulmonary embolism in clinical settings.
引用
收藏
页码:2652 / 2661
页数:10
相关论文
共 26 条
[1]   Guidelines for the early management of adults with ischemic stroke - A guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the atherosclerotic peripheral vascular disease and quality of care outcomes in research interdisciplinary working groups [J].
Adams, Harold P., Jr. ;
del Zoppo, Gregory ;
Alberts, Mark J. ;
Bhatt, Deepak L. ;
Brass, Lawrence ;
Furlan, Anthony ;
Grubb, Robert L. ;
Higashida, Randall T. ;
Jauch, Edward C. ;
Kidwell, Chelsea ;
Lyden, Patrick D. ;
Morgenstern, Lewis B. ;
Qureshi, Adnan I. ;
Rosenwasser, Robert H. ;
Scott, Phillip A. ;
Wijdicks, Eelco F. M. .
STROKE, 2007, 38 (05) :1655-1711
[2]   Fibrinolysis for acute myocardial infarction - Current status and new horizons for pharmacological reperfusion, part 2 [J].
Armstrong, PW ;
Collen, D .
CIRCULATION, 2001, 103 (24) :2987-2992
[3]   Drug therapy - Treatment of acute ischemic stroke [J].
Brott, T ;
Bogousslavsky, J .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (10) :710-722
[4]  
CAMERON HA, 1995, J NEUROSCI, V15, P4687
[5]  
Chandler WL, 1997, CIRCULATION, V96, P761
[6]   Targeted delivery of tissue plasminogen activator by binding to silica-coated magnetic nanoparticle [J].
Chen, Jyh-Ping ;
Yang, Pei-Ching ;
Ma, Yunn-Hwa ;
Tu, Su-Ju ;
Lu, Yu-Jen .
INTERNATIONAL JOURNAL OF NANOMEDICINE, 2012, 7 :5137-5149
[7]   Characterization of chitosan magnetic nanoparticles for in situ delivery of tissue plasminogen activator [J].
Chen, Jyh-Ping ;
Yang, Pei-Chin ;
Ma, Yunn-Hwa ;
Wu, Tony .
CARBOHYDRATE POLYMERS, 2011, 84 (01) :364-372
[8]   Acceleration of Tissue Plasminogen Activator-Mediated Thrombolysis by Magnetically Powered Nanomotors [J].
Cheng, Rui ;
Huang, Weijie ;
Huang, Lijie ;
Yang, Bo ;
Mao, Leidong ;
Jin, Kunlin ;
ZhuGe, Qichuan ;
Zhao, Yiping .
ACS NANO, 2014, 8 (08) :7746-7754
[9]   Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset - The ATLANTIS study: A randomized controlled trial [J].
Clark, WM ;
Wissman, S ;
Albers, GW ;
Jhamandas, JH ;
Madden, KP ;
Hamilton, S .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (21) :2019-2026
[10]  
Cornell R.M., 1996, The Iron Oxide: Structure, Properties, Reactions, Occurance and Uses